anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Eyelid surgery is one of the top five aesthetic procedures. It is performed to improve both appearance and function, but intraoperative bleeding leads to adverse events which perturb patients. The objective of this study was to demonstrate the efficacy of TXA combined with epinephrine in decreasing intraoperative blood loss and postoperative inflammation.
METHODS: This prospective randomized control trial was performed on the 30 eyelids of 15 patients who underwent upper blepharoplasty. One of each patient's eyes was randomly assigned to the TXA group, and the other eye was in the control group. Eyes in the TXA group were given 2% lidocaine with epinephrine (1:100000) mixed with TXA (50 mg/ml) in 1:1 mixture subcutaneously as a local anesthetic. The eyes in the control group received 2% lidocaine with epinephrine (1:100000) diluted with normal saline in 1:1 mixture. Intraoperative blood loss and postoperative swelling were compared between the two groups.
RESULTS: Intraoperative blood loss was significantly higher in the TXA group [4.86 (1.83) ml] than it was in the control group [2.53 (1.49) ml] (p < 0.001). There was no statistically significant difference between the two groups in operative time (p = 0.645), pain score (p = 0.498), lid crease (p = 0.548), or MRD1 (p = 0.626). On postoperative day 7, there was no difference in lid crease (p = 0.879), MRD1 (p = 0.463), pain score (p = 0.934), or ecchymosis (p = 0.976) between two groups.
CONCLUSIONS: TXA in lidocaine with epinephrine was found to increase intraoperative bleeding compared to lidocaine with epinephrine alone, but there was no difference in postoperative swelling or ecchymosis. TXA combined with lidocaine and epinephrine injected subcutaneously should be avoided until additional relevant data are obtained. Further drug interaction study is needed.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
The invention relates to a method for co-expression of Runx2 and Osterix in mesenchymal stem cells or other non-osteoblasts by a special mode that the expression level of Runx2 is less than the expression level of Osterix, thus speeding up the induction of osteoblast differentiation. The invention provides a pharmaceutical composition for prevention or treatment of osteoblast differentiation related diseases. The pharmaceutical composition contains Runx2 protein and Osterix protein, wherein the Runx2 protein content is smaller than the Osterix protein content. The invention also provides application of the Runx2 protein and the Osterix protein in preparation of the pharmaceutical composition for prevention or treatment of osteoblast differentiation related diseases, and in the pharmaceutical composition, the content of the Runx2 protein is less than that of the Osterix protein. The pharmaceutical composition and the special co-expression mode of Runx2 and Osterix provided in the invention can be used for treatment of osteoporosis, osteogenesis imperfecta, periodontal diseases, fractures and other bone diseases, and also can be used for research, development and production of tissue-engineered bones. The invention also provides a method for screening drugs preventing and treating bone diseases.
The purpose of this study is to determine if sperm DNA fragmentation is associated with in vitro fertilization (IVF) outcomes when euploid embryos are transferred. Euploid embryos are those that have a complete set of chromosomes (46, XX or 46, XY). Sperm DNA fragmentation refers to sperm DNA that is damaged or has an altered structure. The sperm chromatin structure assay (SCSA) is a method to evaluate sperm DNA Fragmentation.

Couples will undergo a routine IVF cycle at Reproductive Medicine Associates of New Jersey. Semen specimens collected on the day of ICSI will undergo semen analysis as per routine. An aliquot of semen (0.5- 1mL) will be collected for subsequent evaluation of DNA fragmentation by the Sperm Chromatin Structure Assay (SCSA) testing at SCSA Diagnostics. All embryo biopsies will undergo CCS analysis in the genomics laboratory, Foundation for Assessment and Enhancement of Embryonic Competence.
<P>PROBLEM TO BE SOLVED: To provide a film for a soft capsule and the soft capsule scarcely causing pressure-sensitive adhesiveness on the surface as compared with conventional soft capsules under high-temperature/high humidity.  <P>SOLUTION: The film for the soft capsule contains a protein of Pisum sativum L. Furthermore, the protein of the Pisum sativum L. is a protein contained in an amount of about 20% in grains of the Pisum sativum L. The protein of the Pisum sativum L. is obtained by washing, e.g. the grains of full-ripe yellow pea, drying the washed grains, removing hulls and then extracting the protein component mainly with water. The film for the soft capsule preferably contains the protein of the Pisum sativum L. in an amount of 7.5-20 pts.wt. based on 100 pts.wt. of gelatin.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group. For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability.
This Phase 2b challenge study will investigate colonisation rates, immunologic response, and the safety of BPZE1 vaccination to potentially protect against colonising, virulent wild-type B. pertussis infection in healthy adults using a virulent challenge model. Consenting, eligible participants will receive a single dose of BPZE1 or placebo. 2-4 months later they will be challenged with B. pertussis and admitted to a challenge unit. Participants will remain in the challenge unit for a total of 17 days and 16 nights during which time they will be monitored closely. If a participant develops symptoms of pertussis (per investigator discretion), antibiotic (azithromycin) will be started and the participant will remain in the unit for 3 additional days of observation before discharge. If symptoms of pertussis do not develop, then participants will receive antibiotic (azithromycin) from Days 14-16 of the challenge unit stay. Participants will undergo safety follow-up for at least 6 months post-vaccination and at least 3 months post-challenge, for a total follow-up of 6-7 months.
The invention is based on a novel technology to identify inflammatory responsive elements (IREs) in a mesenchymal stromal cell (MSC) culture that allowed for the development of biomarkers, in particular CD55, CD146, CD271 and MSCA-1, or combinations thereof. The biomarkers of the invention are indicative for an immunomodulatory activity of an MSC. Consequently, the present invention pertains a first aspect, to a method for determining a presence or absence of an immunomodulatory activity of a mesenchymal stromal cell (MSC). Furthermore, in a second aspect, a method for the manufacture of an immunomodulatory preparation derived from an MSC with immunomodulatory activity is disclosed. In a third and fourth aspect, the invention pertains to an immunomodulatory preparation derived from an MSC with immunomodulatory activity and its medical use. In further aspects, the invention also pertains to methods for identifying an immunomodulatory population and an immunomodulatory subpopulation of MSCs with a known presence and/or expression of a biomarker respectively, and to an agent for determining a presence or absence of an immunomodulatory activity of an MSC.
Sickle cell disease (SCD) is the most common inherited monogenetic disorder. Chronic and acute pain are hallmark features of SCD involving neural and vascular injury and inflammation. Mast cells reside in the vicinity of nerve fibers and vasculature, but how they influence these structures remains unknown. We therefore examined the mechanism of mast cell activation in a sickle microenvironment replete with cell-free heme and inflammation. Mast cells exposed to this environment showed an explosion of nuclear contents with the release of citrullinated histones, suggestive of mast cell extracellular trap (MCET) release. MCETs interacted directly with the vasculature and nerve fibers, a cause of vascular and neural injury in sickle cell mice. MCET formation was dependent upon peptidylarginine deiminase 4 (PAD4). Inhibition of PAD4 ameliorated vasoocclusion, chronic and acute hyperalgesia, and inflammation in sickle mice. PAD4 activation may also underlie neutrophil trap formation in SCD, thus providing a novel target to treat the sequelae of vascular and neural injury in SCD.
Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
Dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [Schedule III (CIII)] under the Controlled Substances Act. Both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration.

Chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgment, and perception. The etiology of these impairments is unknown, but may be associated with the complex process of addiction rather than an isolated effect of the drug. No such decrements in psychological, social or neurological status have been associated with the administration of dronabinol capsules for therapeutic purposes.

In an open-label study in patients with AIDS who received dronabinol capsules for up to five months, no abuse, diversion or systematic change in personality or social functioning were observed despite the inclusion of a substantial number of patients with a past history of drug abuse.

An abstinence syndrome has been reported after the abrupt discontinuation of dronabinol in volunteers receiving dosages of 210 mg/day for 12 to 16 consecutive days. Within 12 hours after discontinuation, these volunteers manifested symptoms such as irritability, insomnia, and restlessness. By approximately 24 hours post-dronabinol discontinuation, withdrawal symptoms intensified to include “hot flashes”, sweating, rhinorrhea, loose stools, hiccoughs and anorexia.

These withdrawal symptoms gradually dissipated over the next 48 hours. Electroencephalographic changes consistent with the effects of drug withdrawal (hyperexcitation) were recorded in patients after abrupt dechallenge. Patients also complained of disturbed sleep for several weeks after discontinuing therapy with high dosages of dronabinol.
Sarcopenia and osteoporosis do not develop independently. Rather, there is a close physiological and pathological relationship between them, often leading to the condition known as osteo-sarcopenia. This relationship also provides a basis for exploring the common mechanisms of muscle regeneration and bone remodeling. In the process of muscle and bone degeneration, inflammation is an important mechanism for disease progression, and the balance between regulatory T cells (Tregs) and Th17 cells is an important regulatory mechanism for immune equilibrium and inflammatory response. If the number and function of Tregs are impaired, coupled with an increase in the activity of Th17 cells, an imbalance between Tregs and Th17 cells occurs, leading to an increase in inflammatory response and an accumulation of tissue damage, and ultimately impairing myogenic and osteogenic functions. By regulating the Treg/Th17 cell immune balance, symptoms of muscle and bone degeneration can be improved.
Axillary node clearance (ANC) is a controversial intervention in the surgical treatment of breast cancer. Different studies have shown that in some patients with infiltrated axillary lymph nodes but low tumor burden, ANC can be safely omitted. However, indications for ANC persist in nowadays for patients with positive axillary lymph nodes and upfront surgery and patients with positive lymph nodes after neoadjuvant treatment. The present prospective study will evaluate the ability to establish an axillary tumor load with two steps. The first step will be a preoperative predefined systematic axillary ultrasound imaging workflow. The second step will be the tumor load evaluation of suspicious and sentinel axillary lymph nodes. We will also evaluate which patients have infiltrated nodes only beneath the second intercostobrachial nerve. The trial intends to identify patients for who a complete axillary node clearance could be spared.
<P>PROBLEM TO BE SOLVED: To solve the problem that compositions originated from chitosan and exhibiting new characteristics are so much not be obtained, although a composition holding the original properties of the chitosan and exhibiting new characteristics is required.  <P>SOLUTION: The subject composition contains a chitosan derivative obtained by reacting 100 pts. wt. of chitosan with 1.86 to 22.3 pts. wt. of formaldehyde and a polybasic carboxylic acid having two or more active CH groups in an amount of 0.2 to 1.5 moles per mole of the formaldehyde. A method for producing the composition is provided. A film formed from the composition and a hemostatic agent comprising the film are also disclosed.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
BACKGROUND AND OBJECTIVE: With lumbar spine fusion being one of the most commonly performed spinal surgeries, investigating common complications such as adjacent segment disease (ASD) is a high priority. To the authors' knowledge, there are no previous studies investigating the utility of the preoperative magnetic resonance imaging-based vertebral bone quality (VBQ) score in predicting radiographic and surgical ASD after lumbar spine fusion. We aimed to investigate the predictive factors for radiographic and surgical ASD, focusing on the predictive potential of the VBQ score.
METHODS: A single-center retrospective analysis was conducted of all patients who underwent 1-3 level lumbar or lumbosacral interbody fusion for lumbar spine degenerative disease between 2014 and 2021 with a minimum 12 months of clinical and radiographic follow-up. Demographic data were collected, along with patient medical, and surgical data. Preoperative MRI was assessed in the included patients using the VBQ scoring system to identify whether radiographic ASD or surgical ASD could be predicted.
RESULTS: A total of 417 patients were identified (mean age, 59.8 ± 12.4 years; women, 54.0%). Eighty-two (19.7%) patients developed radiographic ASD, and 58 (13.9%) developed surgical ASD. A higher VBQ score was a significant predictor of radiographic ASD in univariate analysis (2.4 ± 0.5 vs 3.3 ± 0.4; P < .001) and multivariate analysis (odds ratio, 1.601; 95% CI, 1.453-1.763; P < .001). For surgical ASD, a significantly higher VBQ score was seen in univariate analysis (2.3 ± 0.5 vs 3.3 ± 0.4; P < .001) and served as an independent risk factor in multivariate analysis (odds ratio, 1.509; 95% CI, 1.324-1.720; P < .001). We also identified preoperative disk bulge and preoperative existence of adjacent segment disk degeneration to be significant predictors of both radiographic and surgical ASD. Furthermore, 3-level fusion was also a significant predictor for surgical ASD.
CONCLUSION: The VBQ scoring system might be a useful adjunct for predicting radiographic and surgical ASD.
The present invention relates to medicine for curing digestive canal ulcer diseases and a preparation method thereof. The present invention is characterized in that the medicine for curing digestive canal ulcer diseases is prepared from the following raw materials of 80 to 120 of elephant hide, 80 to 120 of bletilla tuber, 80 to 120 of fritillaria thunbergii, 80 to 120 of patent swertia herb, 4 to 6 of orange peel, 4 to 6 of chicken gizzard-membrane, 80 to 120 of cuttlebone and 80 to 120 of liquorice which are finally prepared into superfines of 300 to 500 meshes. Besides unique medicine combination, the medicine for curing digestive canal ulcer diseases of the present invention has the effects of acid removal, pain alleviation, ulcer healing and hemostasis. The functions of symptom improvement of the medicine for curing digestive canal ulcer diseases of the present invention to ulcer healing, pain easement, tongue pulses, etc., are obviously better than those of other medicine. The medicine for curing digestive canal ulcer diseases of the present invention can effectively control or eliminate pathopoiesis attack factors, and enhance defensivenessfactors. The medicine for curing digestive canal ulcer diseases of the present invention can simultaneously cure principal and subordinate symptoms, enhance organism immunizing power, reduce relapse rate, and sufficiently incarnate the integral recuperative medical care superiority, such as multiple targets and multiple links, of traditional Chinese physician. The medicine for curing digestive canal ulcer diseases of the present invention has preferable clinical curative effects and is prepared through modern high-tech superfines technologies and advanced sterilization technologies, the raw materials are furthest used, and resources are saved. The medicine for curing digestive canal ulcer diseases of the present invention has strong surface absorbing capacity and avidity and can effectively attach to the gastrointestinal.
NEW MATERIAL:The compound of formula I (R<1> is lower alkyl). EXAMPLE:4-Carboxyethylcarbonylaminobenzoic acid 2-(diethylamino)ethyl ester. USE:A local anesthetic useful in the anesthetic treatment for operation, nerve block and pain clinic, etc. The anesthetic period is twice that of the conventional anesthetic. PREPARATION:The compound of formula I can be produced by reacting a compound of formula II with succinic acid in an inert solvent (e.g. chloroform, dichloroethane, benzene or toluene). The succinic acid is preferably used as it is or in the form of acid anhydride or active ester. The compound of formula I has development and strength of anesthetic action comparable to those of procaine.
The invention provides a collagen and a collagen polypeptide, wherein, the weight percentage of hydroxylysine is more than 1.3 percent. The invention also provides the preparation technology and the application of the collagen and the collagen polypeptide. The invention can make full use of inexpensive raw materials including the fish skin and fish scale of tilapias to produce products with high added value. The collagen polypeptide is used for treating arthritis with a definite drug effect, and the clinical dose is considerably less than other collagen polypeptides. The collagen polypeptide can solve the pollution problem of fish skin wastes, and at the same time avoid the risk of infectious diseases which can be caused by the collagen of land animals. The collagen and the collagen polypeptide have the advantages of considerable economic benefits, energy conservation and environmental protection, simple process equipment, low cost and easy industrialization.
Children with rare disease and their caregivers are distressed and stressed to deal with the disease and daily life, and their parent-child relationships are also challenging. Although social robots have been used to improve patients' and caregivers' well-being in clinical settings, there still needs to be family-centered, child-friendly, convenient, and feasible interventions for patients with rare diseases and their families. This study aims to evaluate the feasibility and acceptability of a social robot intervention for providing family-based care for rare disease families and explore the effectiveness of the social robot intervention in improving the parent-child relationships and alleviating stress and anxiety for rare disease patients and their parents. A single-group, pretest-posttest feasibility study will be conducted in a medical center in Northern Taiwan. Of 21 dyads of 8- to 19-year-old children with rare diseases and their parents will be enrolled. The dyads will interact with the social robot PARO in each 30-minute course every two weeks for four courses. The retention rate will be calculated after the study, and the Friedman's test and Wilcoxon signed rank test will analyze the changes in the parent-child relationship, the anxiety, the perceived stress scales, and the heart rate variability. The content analysis will be used to analyze the interview data to delve into the child-parent-robot interaction and the effectiveness of the social robot intervention in the patients and the parents. This study is expected to provide a feasible and effective intervention to improve the psychological and social health of children with rare diseases and their caregivers and provide a reference for future randomized controlled trials of social robots in pediatric care.
The invention provides a rodenticide comprising cellulosic material which is non-toxic to humans but which causes rodents to excrete body fat and/or adipose tissue. Suitable material is obtainable from the core of the cob of maize hybrid DK 446, a hybrid characterised by normally growing to a height of 2.7 to 3.3 metres (9 to 11 feet) and by normally having a single giant ear of corn. The cellulosic material is mixed with a bait attractant such as sugar beet or unrefined molasses and formed into pellets. The rodenticide is non-toxic when fed at controlled dosage levels (e.g. up to 15 g/kg per day) but toxic when the rats are allowed free access. Maize hybrids DK 401, DK 442, DK 512, DK 560, DK 588, DK 591, DK 604, DK 628, DK 634 and DK 512wx may also be used instead of hybrid DK 446.
Menopause-related musculoskeletal (MSK) disorders include osteoporosis, osteoarthritis (OA), sarcopenia and sarco-obesity. This review focuses on the applications of nuclear medicine for the functional imaging of the aforementioned clinical conditions. Bone Scan (BS) with 99mTc-labeled phosphonates, alone or in combination with MRI, can identify "fresh" vertebral collapse due to age-associated osteoporosis and provides quantitative parameters characterized by a good correlation with radiological indices in patients with OA. 18F-NaF PET, particularly when performed by dynamic scan, has given encouraging results for measuring bone turnover in osteoporosis and allows the evaluation of subchondral bone metabolic activity in OA. FDG PET can help discriminate between pathological and nonpathological vertebral fractures, especially by applying appropriate SUV-based thresholds. In OA, it can effectively image inflamed joints and support appropriate clinical management. Preliminary evidences suggest a possible application of FDG in sarco-obesity for the detection and quantification of visceral adipose tissue (VAT). Further studies are needed to better define the role of nuclear medicine in menopause-related MSK disease, especially as regards the possible impact of new radiopharmaceuticals (ie, FAPI and RGD peptides) and recent technological advances (eg, total-body PET/CT scanners).